DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
46 hedge funds and large institutions have $5.18M invested in DMK Pharmaceuticals Corporation Common Stock in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 12 closing their positions.
911% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $131K
89% more capital invested
Capital invested by funds: $2.74M → $5.18M (+$2.45M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 47 → 46 (-1)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
+$847K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$367K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$213K |
| 4 |
VCA
Verdence Capital Advisors
Hunt Valley,
Maryland
|
+$74.9K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$47.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$139K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$43.8K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$42K |
| 4 |
Millennium Management
New York
|
-$34.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19K |
DMK Hedge Fund Activity: Q3 2020 in Review
46 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2020, worth a combined $5.18M — up 89% from $2.74M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DMK and 11 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 6 added.
The largest buyer was Maven Securities, opening a new position worth an estimated $847K. The largest seller was Geode Capital Management, cutting an estimated $139K.
- 46 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2020, down from 47 in Q2 2020.
- Funds reported $5.18M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2020, up 89% quarter-over-quarter.
- 11 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2020 and 12 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2020 was Maven Securities, an estimated $847K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2020 was Geode Capital Management, an estimated $139K sold.
Based on aggregated 13F filings for Q3 2020.